Recursion Pharmaceuticals, Inc. (RXRX)
NASDAQ: RXRX · Real-Time Price · USD
4.780
+0.660 (16.02%)
At close: Oct 5, 2026, 4:00 PM EDT
4.770
-0.010 (-0.21%)
Pre-market: Oct 6, 2026, 4:31 AM EDT
Recursion Pharmaceuticals Revenue
Recursion Pharmaceuticals had revenue of $7.67M in the quarter ending June 30, 2026, a decrease of -60.10%. This brings the company's revenue in the last twelve months to $54.86M, down -15.08% year-over-year. In the year 2025, Recursion Pharmaceuticals had annual revenue of $74.68M with 26.92% growth.
Revenue (ttm)
$54.86M
Revenue Growth
-15.08%
P/S Ratio
46.73
Revenue / Employee
$91,427
Employees
600
Market Cap
2.56B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 74.68M | 15.84M | 26.92% |
| Dec 31, 2024 | 58.84M | 14.26M | 32.00% |
| Dec 31, 2023 | 44.58M | 4.73M | 11.88% |
| Dec 31, 2022 | 39.84M | 29.67M | 291.46% |
| Dec 31, 2021 | 10.18M | 6.22M | 156.89% |
| Dec 31, 2020 | 3.96M | 1.64M | 70.85% |
| Dec 31, 2019 | 2.32M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Harmony Biosciences Holdings | 959.90M |
| ADMA Biologics | 512.28M |
| Aurinia Pharmaceuticals | 311.51M |
| Vericel | 306.30M |
| Maravai LifeSciences Holdings | 208.78M |
| Viridian Therapeutics | 71.13M |
| Immunome | 4.02M |
RXRX News
- 8 hours ago - Cathie Wood’s ARK Investment buys 1.5M shares of Recursion Pharmaceuticals today - TheFly
- 14 days ago - Tempus AI, Recursion extend data license agreement, enter new license agreement - TheFly
- 14 days ago - Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion's RNA Foundation Model - Business Wire
- 20 days ago - Recursion Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 7 weeks ago - Recursion Pharmaceuticals price target lowered to $5.30 from $5.50 at Morgan Stanley - TheFly
- 7 weeks ago - Recursion Pharmaceuticals Transcript: Bank of America SMID Cap Virtual Conference - Transcripts
- 2 months ago - Recursion Pharmaceuticals Earnings Call Transcript: Q2 2026 - Transcripts
- 2 months ago - Recursion Pharmaceuticals Quarterly report: Q2 2026 - Filings